Objective. The aim of the present study was to determine whether asymptomatic heart failure (HF) in the workplace is subject to the health worker effect, making screening using conventional risk factors combined with a cardiac biomarker, namely N-terminal pro B-type natriuretic peptide (NT-proBNP), as useful as in the general population.
Introduction
The aging population has led to a rising prevalence of heart failure (HF). 1 Morbidity, mortality and cost of care remain high, so there is an urgent need for early detection, when early treatment may more favourably affect the course of the disease. 2 Many studies [3] [4] [5] have shown the benefit of early diagnosis and treatment. Epidemiological studies have observed that 50% or more of those with left ventricular (LV) dysfunction are asymptomatic, undiagnosed and presumably untreated. 6 We formulated the hypothesis that 'asymptomatic' LV dysfunction may not be the same as 'undiagnosed' LV dysfunction; furthermore, little work has been undertaken into the quality of life and functional capacity of those with cardiac remodelling that underlies ventricular dysfunction. [4] [5] [6] This makes the early detection and treatment of asymptomatic LV dysfunction (ALVD) important. However, if the healthy worker effect (HWE) operates in ALVD, which is our hypothesis, screening in the workplace would likely not be appropriate. The HWE means workers with high HF risk may have already left the work force. 7, 8 The workplace has been shown to be an important medium of health promotion and screening. [9] [10] [11] [12] [13] [14] If the HWE does not operate, screening for HF and ALVD in the workplace may permit earlier treatment, potentially enhancing quality of life and survival, preserving working life and productivity and doing so at containable cost. Screening is important because effective therapy exists for LV systolic dysfunction. 15 Therapy for LV diastolic dysfunction remains empirical.
The SCReening Evaluation of the Evolution of New Heart Failure Study (SCREEN-HF) 16 combined conventional risk factors and the cardiac biomarker N-terminal pro B-type natriuretic peptide (NT-proBNP) to target an asymptomatic population at high risk for subsequent development of HF to investigate whether NT-proBNP would be an effective screening strategy for the detection of ventricular dysfunction in this high-risk population.
NT-proBNP is the 76-amino acid N-terminal inactive protein that is cleaved from its precursor proBNP to release BNP. Both NT-proBNP and BNP are released from the ventricle in response to pressure or stretch. 16 The present study analysed the working status of participants within the SCREEN-HF 16 population dataset to determine whether workplace screening for ALVD may be a feasible.
Methods
Between June 2007 and December 2009, a Victorian population deemed at high risk for the development of HF was recruited from members of a private health insurer.
Inclusion criteria were age !60 years and at least one HF risk factor as follows: history of coronary artery disease (myocardial infarction, angina, coronary angioplasty or coronary artery bypass grafts), stroke, valvular heart disease, atrial fibrillation, hypertension or diabetes treated for at least 2 years, or known renal impairment. Exclusion criteria were a pre-existing HF diagnosis or known ventricular dysfunction.
Study subjects responded to a letter of invitation from the insurer by returning a brief HF risk factor questionnaire to the study centre. If inclusion criteria were confirmed by telephone interview with a researcher, the subject was invited to participate by attendance at the study centre.
After informed written consent had been obtained at the baseline visit, participants completed a researcher-administered structured questionnaire.
Past medical and medication history, HF symptoms and activity levels were sought from working and non-working participants. Anthropomorphic and blood pressure measurements were made and blood samples were taken for determination of urea, electrolytes, creatinine, full blood count and NT-proBNP concentrations.
Serum NT-proBNP concentrations were measured by electrochemiluminescence immunoassay using an Elecsys instrument (Roche Diagnostics, Basel, Switzerland). The lower limit of detection of this assay was 0.6 pM.
Following the baseline visit, plasma NT-proBNP concentrations were used to further stratify participants. Those in the top quintile (classified as >31.8 pmol L ) were invited to attend a second study visit.
At the second visit, participants underwent clinical assessment, including blood pressure measurement, cardiac and lung auscultation, fluid status and an echocardiogram [17] [18] [19] [20] [21] assessment by the study cardiologist (MM). ). Univariate and multivariate logistic regression analysis was used to investigate the relationship between risk factors, NT-proBNP and ventricular structure and function. Because of their skewed distribution, NT-proBNP concentrations were log-transformed for regression analyses. Interobserver reproducibility was investigated and summarised with concordance correlation coefficients. 
Statistical analysis

Results
Letters of invitation and questionnaires were sent to 44 000 members of a private health insurance fund who were over 60 years of age and living in Victoria. Just over 25% of questionnaires (n = 11 046) were returned. Consecutive respondents were telephone screened (n = 9256) until 3550 met the inclusion criteria and attended for a baseline visit to enrol in the study after providing informed consent. Of the remaining respondents, 4527 members did not meet inclusion or exclusion criteria and 1179 eligible members who met declined to enrol in the study.
Following further stratification using serum NT-proBNP concentrations measured at the baseline visit, participants in the top NT-proBNP quintile and 51 consecutive participants in the bottom quintile were invited to attend for a second visit at which they were given an echocardiogram.
In all, 3550 participants enrolled and attended the baseline visit. The mean (AE s.d.) age of subjects was 70.4 AE 6.7 years (range 65 -92 years), 55% were male and 14.6% were known to be in work (19.7% of respondents were workers). Seven hundred participants from the top NT-proBNP quintile (45 of these participants (5.9%) later withdrew) and 61 participants from the bottom quintile (10 later withdrew) were invited to attend a second visit and 655 and 51, respectively, completed echocardiography.
Fifteen participants who enrolled in the study were found to meet exclusion criteria (pre-existing HF) and were excluded from analysis.
Primary income source was ascertained for 71% of the cohort, with approximately 30% did not completing income questions (Table 1) . Those who did not respond, compared with responders, were older (72.0 AE 7.1 vs 69.6 AE 6.3 years; P < 0.0001) and more likely to report a history of diabetes (odds ratio (OR) 1.2; P = 0.04), but there were no significant differences in gender, history of coronary disease, hypertension or obesity between the two groups. In the top NT-proBNP quintile (>30 pmol/L NT-proBNP; i.e. participants who underwent an echocardiogram), a larger percentage did not complete the income question (36% vs 29% from the overall cohort); again non-responders were older than responders (75.0 AE 7.5 vs 73.4 AE 6.5 years; P = 0.003), but there were no significant differences between the groups in terms of gender, past medical history or LV systolic or diastolic function.
Of the 2487 responders in the study population, only 21% reported that paid work or unemployment benefits were their primary source of income. 'Workers' (self-reported full-time, part-time, casual work or unemployment benefits as the primary source of income) compared with 'retirees' (self-reported selffunded or pension as the primary source of income) were younger (65.6 AE 5.1 vs 70.7 AE 6.1 years, respectively; P < 0.001; Table 2 ), more likely to be male (OR 2.0; P < 0.0001) and less likely to have a history of coronary artery disease (OR 0.6; P < 0.0001). However, there were no differences in the history of diabetes, hypertension or obesity between workers and retirees.
Workers in the top NT-proBNP quintile, compared with retirees in that quintile, were younger (68.3 AE 7.1 vs 74.1 AE 6.1 years, respectively; P < 0.0001) but there was no significant difference in mean LV ejection fraction (LVEF) between the two groups (55.8 AE 7.6% vs 56.8 AE 6.8%, respectively; P = 0.3; Table 3 ). Mean LVEF was tabulated against source of income for respondents (Table 4) to show no significant difference in the burden of moderate to severe diastolic function between workers and retirees (21.9% vs 22% respectively; OR 1.0; P = 0.9).
HF risk factors
Comparing across the five NT-proBNP quintiles, mean age increased with high NT-proBNP levels (OR 1.13; 95% confidence interval (CI) 1.12-1.14; P < 0.001). Although the presence of an HF risk factor was required for inclusion in the study, those in the higher NT-proBNP quintiles were significantly more likely to have a history of coronary artery disease (OR 2.3; 95% CI 2.0-2.7; P < 0.001), stroke (OR 1.7; 95% CI 1.4-2.0; P < 0.001), impaired renal function (estimated glomerular filtration rate <60 mL min -1 1.73 m -2 ; OR 2.7; 95% CI 2.3-3.1; P < 0.001) or atrial fibrillation (OR 5.0; 95% CI 4.1-6.2; P < 0.001).
Conversely, diabetes (OR 0.8; 95% CI 0.7-0.9; P = 0.009), hypertension (OR 0.8; 95% CI 0.7-0.9; P = 0.007) and obesity (OR 0.9; 95% CI 0.8-1.0; P = 0.02) were more common in the lowest NT-proBNP quintile. Multiple HF risk factors were also more likely to be present in those in the highest NT-proBNP quintile (OR 1.5; 95% CI 1.4-1.6; P < 0.001).
Participants who were older, female or had a history of coronary artery disease were significantly less likely to be working. There was no significant correlation between work status and history of atrial fibrillation, diabetes, hypertension, stroke or serum BNP concentrations (Table 5) .
LV systolic function
Participants in the upper NT-proBNP quintile who underwent an echocardiogram (n = 710), compared with those in the bottom quintile (n = 51), were older (74.5 AE 6.8 vs 67.2 AE 4.6 years, respectively; P < 0.001) and more were female (OR 1.17; 95% CI 1.12-1.24; P < 0.001). Those in the top quintile were less likely to be in work the older they were and if they were female (Table 6) .
Forty-four participants (6.6%; 95% CI 4%-8%) had impaired LV systolic function (LVEF 45%); these were all in the top NT-proBNP quintile (i.e. elevated NT-proBNP concentrations). The mean LVEF of participants was significantly greater in the lowest compared with the highest NT-proBNP quintile (59.5 AE 5.7% vs 56.5 AE 7.4%, respectively; P = 0.003). Male gender, coronary artery disease, hypertension and log NTproBNP concentration were associated with impaired ejection fraction. In a further multivariate analysis, log NT-proBNP concentration was independently associated with impaired LVEF (P < 0.001) after adjustment for age, sex, coronary artery disease, diabetes, hypertension and obesity.
LV diastolic function
Diastolic function was assessed in 553 participants; it was not assessed in 163 participants because of rhythm or valve pathology. Moderate to severe diastolic dysfunction was observed in 131 participants (24%; 95% CI 20%-27%) and was significantly more prevalent in the highest NT-proBNP quintile (n = 128/503) than in the lowest quintile (n = 3/50; OR 5.4; 95% CI 1.7-17.7; P = 0.005). Although diastolic dysfunction worsened with age, this association did not reach statistical significance. Diabetes was associated with moderate to severe diastolic dysfunction after adjustment for age and gender (OR 1.86; 95% CI 1.86-2.98; P = 0.01), as was log NT-proBNP concentration (OR 1.67; 95% CI 1.15-2.43; P = 0.008). Coronary artery disease, hypertension and obesity were not associated with diastolic dysfunction. In a further multivariate analysis, log NT-proBNP concentration was independently associated with moderate to severe diastolic dysfunction (P = 0.006) after adjustment for age, sex, coronary artery disease, diabetes, hypertension and obesity.
ALVD in workers
ALVD was observed in more than 20% of participants with elevated NT-proBNP levels (>30 pM). However, there was no difference in LV systolic (P = 0.08) or diastolic function (P = 0.7) between workers and non-workers (of all types).
Discussion
In the present study, we observed a significant burden of asymptomatic LV systolic and diastolic dysfunction in an undiagnosed population with risk factors for HF and increased concentrations of the biomarker NT-proBNP. Increased NT-proBNP was associated with ALVD independent of established HF risk factors, with no difference in LV systolic (P = 0.3) or diastolic function (P = 0.9) between workers and non-workers. Hence, HWE does not operate in ALVD and the hypothesis that workers in the population would have a lesser burden of ALVD is disproved. Elevated biomarkers have been associated with systolic dysfunction in several studies, but these have included pre-existing HF, [23] [24] [25] and the use of NT-proBNP at a broader population level has not been demonstrated previously to be cost-effective. In the PROBE-HF study (The Role of N-terminal PRO-Brain Natriuretic Peptide and Echocardiography for Screening Asymptomatic Left Ventricular Dysfunction in a Population at High Risk for Heart Failure), NT-proBNP was useful in excluding ventricular dysfunction, but less effective at predicting the presence of dysfunction. 26 As a sensitive marker of volume overload, myocardial stretch and ventricular dysfunction, our study findings indicate that NT-proBNP may have a role in screening asymptomatic high-risk populations for the detection of ventricular dysfunction or early HF when therapeutic options for prevention and treatment are likely to be more effective.
The prevalence of CHF in the Western world is estimated to be 1.5%-2% of the population, with 26 million people affected worldwide. 27, 28 Nearly £1 billion, or 1% of the British National Health Service budget, is devoted to HF with hospitalisation the main cost driver. 28 Importantly, the SOLVD investigators showed that the early treatment of CHF led to fewer patients being hospitalised. The findings of the present study may help better target existing workplace health programs. The present study identified age, male gender and coronary artery disease as important cardiac risk factors in predicting work longevity. However, many current workplace-based health programs concentrate on better management of diabetes and obesity, risk factors the present study was unable to show as predictors of longevity in the workplace.
Limitations
The high-risk population evaluated in the present study was recruited from private health insurance membership, which may affect the generalisation of the study findings to the general working population. Inclusion, however, was defined by HF risk factors (age plus underlying pathology), and these should not differ greatly between the study population and the general working population.
In addition, although only 2487/3550 participants responded to questions regarding income source, but the study's workrelated conclusions remain statistically significant. 
Conclusion
A large burden of asymptomatic ventricular dysfunction was observed in older subjects with plasma NT-proBNP concentrations in the top quintile and this was independent of conventional risk factors and work status, suggesting that the HWE does not operate in ALVD. This means combining plasma NT-proBNP testing in the older workforce with conventional HF risk factors in the workplace may help identify those with ALVD and thus at greatest risk of developing HF. We have also provided an economic argument for the screening strategy suggested on the basis of the results of the present study 28 and identified important cardiac risk factors in predicting work longevity. These findings may increase the efficiency and cost-effectiveness of future workplace health programs.
